Incyte Is Maintained at Outperform by Oppenheimer
Incyte Analyst Ratings
Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Cuts Target Price to $81
Express News | Incyte : Oppenheimer Cuts Target Price to $81 From $84
Express News | Incyte Corp : Oppenheimer Cuts Target Price to $81 From $84
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
Express News | Incyte Corp : Leerink Partners Raises Target Price to $84 From $80
What to Expect From Incyte's Q2 2024 Earnings Report
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Vitiligo Therapeutic Assessment Analysis Report 2024: Comprehensive Insights About 20+ Companies and 20+ Pipeline Drugs Featuring Key Players - AbbVie, Pfizer, Incyte, Ahammune Biosciences, & Amgen
Most Shorted S&P 500 Stocks in June
Is Incyte Corporation's (NASDAQ:INCY) Recent Stock Performance Tethered To Its Strong Fundamentals?
Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June
Is Incyte Corporation's (NASDAQ:INCY) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Goldman Sachs Adjusts Price Target on Incyte to $61 From $60, Maintains Neutral Rating
Express News | Incyte Corp : JP Morgan Cuts Target Price to $59 From $60
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
Form 144 | Incyte(INCY.US) Officer Proposes to Sell 488.88K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 9, $Incyte(INCY.US)$ Officer BARRY FLANNELLY intends to sell 8,148 shares of its common stock on Jul 9, with a total market value of approximately $488.88K. BARRY
S&P 500, Nasdaq Set New Closing Records After Fed Chair Powell's Comments
S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?